What's in Case Comprehensive Cancer Center's pipeline?

Case Comprehensive Cancer Center has 5 drugs in our index: 0 marketed, 0 filed, 4 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Case Comprehensive Cancer Center's portfolio?

Top competitors by shared drug class: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Bayer, Biogen, Celgene, Chonnam National University Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/case-comprehensive-cancer-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Case Comprehensive Cancer Center — Portfolio Competitive Intelligence Brief

Case Comprehensive Cancer Center pipeline: 0 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Methotrexate (low dose)	Methotrexate (low dose)	phase 3	Antimetabolite; folate antagonist	Dihydrofolate reductase (DHFR)	Oncology; Immunology
recombinant interferon alfa-2b	recombinant interferon alfa-2b	phase 3	Interferon	Interferon-alpha receptor	Oncology
O6-benzylguanine	O6-benzylguanine	phase 3	DNA repair inhibitor / Alkyltransferase inhibitor	O6-alkylguanine-DNA alkyltransferase (AGT)	Oncology
tamsulosin and/or dutasteride	tamsulosin and/or dutasteride	phase 3	Alpha-1 adrenergic receptor antagonist and 5-alpha-reductase inhibitor	Alpha-1 adrenergic receptor and 5-alpha-reductase	Urology

Therapeutic area mix

Oncology · 2
Oncology; Immunology · 1
Urology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
Bayer · 1 shared drug class
Biogen · 1 shared drug class
Celgene · 1 shared drug class
Chonnam National University Hospital · 1 shared drug class
Cinnagen · 1 shared drug class
EMD Serono · 1 shared drug class
Active Biotech AB · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Case Comprehensive Cancer Center:

Cite this brief

Drug Landscape (2026). Case Comprehensive Cancer Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/case-comprehensive-cancer-center. Accessed 2026-05-16.